Raymond James analyst John Ransom reiterated a Market Perform rating on Amedisys (NASDAQ: AMED).The analyst comments "We are updating our ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE